- ICH GCP
- EU Kliniske forsøgsregister
Seneste forsøg
EudraCT Number: 2004-000715-26 | Sponsor Protocol Number: BO17920 | Start Date: 2005-02-02 | |||||||||||
Sponsor Name: F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Le... | |||||||||||||
Medical condition: Adjuvant treatment for patients who have undergone surgery for Colon cancer, AJCC/UICC high-risk Stage II & stage III | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) DE (Completed) HU (Completed) GB (Completed) CZ (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004249-16 | Sponsor Protocol Number: F02207GE204 | Start Date: 2005-02-02 | ||||||
Sponsor Name: PIERRE FABRE MEDICAMENT | ||||||||
Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY | ||||||||
Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i... | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-002925-39 | Sponsor Protocol Number: 040826 | Start Date: 2005-02-02 | ||||||
Sponsor Name: Kliniken för onkologi, Karolinska Universitetssjukhuset, Solna | ||||||||
Full Title: A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma. | ||||||||
Medical condition: Metastatic melanoma | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: SE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003516-35 | Sponsor Protocol Number: CLINEMAT 66 | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: AZIENDA OSPEDALIERA UMBERTO I | |||||||||||||
Full Title: Proposal of pilot study for evaluation of Campath-1h activity as second line therapy of mantle cell lymphoma | |||||||||||||
Medical condition: Second line salvage therapy of relapsed or refractory mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001613-34 | Sponsor Protocol Number: 304004 | Start Date: 2005-02-01 | ||||||
Sponsor Name: Schering AG | ||||||||
Full Title: A multi-center, double-blind, double-dummy, controlled, randomized study to evaluate cycle control and safety of a four-phasic oral contraceptive containing estradiol valerate and dienogest (SH T00... | ||||||||
Medical condition: Contraception | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: DE (Completed) CZ (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-003814-40 | Sponsor Protocol Number: FE200486 CS12A | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer | |||||||||||||
Medical condition: Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000369-37 | Sponsor Protocol Number: NKT102245 | Start Date: 2005-02-01 | ||||||
Sponsor Name: GlaxoSmithKline Group of Companies | ||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun... | ||||||||
Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV) | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000587-26 | Sponsor Protocol Number: CFTY720A2218E1 | Start Date: 2005-02-01 | |||||||||||
Sponsor Name: Novartis Pharma Services AG | |||||||||||||
Full Title: A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroid... | |||||||||||||
Medical condition: Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002255-14 | Sponsor Protocol Number: MM17385 | Start Date: 2005-02-01 | ||||||
Sponsor Name: F. Hoffmann-La Roche Ltd | ||||||||
Full Title: Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administ... | ||||||||
Medical condition: Study in women with postmenopausal osteoporosis. | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) GB (Completed) ES (Completed) DK (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-003749-42 | Sponsor Protocol Number: EUROPA | Start Date: 2005-02-01 | ||||||
Sponsor Name: Enric Pedrol Clotet. Unidad Enfermedades Infecciosas.Hospital de Granollers | ||||||||
Full Title: ESTUDIO DE LOS CAMBIOS EN EL RECUENTO DE LINFOCITOS CD4 TRAS LA SUSTITUCIÓN DE TENOFOVIR POR ABACAVIR EN PACIENTES CON UNA PAUTA HAART QUE INCLUYA DDI + TENOFOVIR Y CON SUPRESIÓN VIRAL | ||||||||
Medical condition: HIV infected patients | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: ES (Ongoing) | ||||||||
Trial results: (No results available) |